Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric oncology group trial

American Journal of Pediatric Hematology/Oncology

Volumn 23, Issue 6, 2001, Pages 340-348

  Ferguson, William S ^a,j   Harris, Michael B ^b   Goorin, Allen M ^c   Gebhardt, Mark C ^d   Link, Michael P ^f   Shochat, Stephen J ^g   Siegal, Gene P ^h   Devidas, Meenakshi ^i,j   Grier, Holcombe E ^e  

^a BROWN UNIVERSITY   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ Children's Oncology Group Statistics and Data Center   (United States)

^j The Children s Oncology Group   (United States)

more..

Author keywords

Carboplatin; Metastatic osteosarcoma; Phase II window

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; LUNG METASTASIS; MALE; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; COMBINED MODALITY THERAPY; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IFOSFAMIDE; INFUSIONS, INTRAVENOUS; MALE; METHOTREXATE; OSTEOSARCOMA; PREOPERATIVE CARE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034841885     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200108000-00004     Document Type: Article

References (62)

1. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314:1600-6.
2. Eilber F, Giuliano A, Eckardt J, et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987; 5:21-6.
3. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol 1997; 15:76-84.
4. Meyers PA, Heller G, Healey J, et al. Chemotherapy for non-metastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10:5-15.
5. Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998; 16:2452-8.
6. Simon MA, Aschliman MA, Thomas N, et al. Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg Am 1986; 68:1331-7.
7. Marcove RC, Shetch DS, Healey J, et al. Limb-sparing surgery for extremity sarcoma. Cancer Invest 1994; 12:497-504.
8. Kempf-Bielack B, Bielack S, Bieling P, et al. Local failure (LF) of osteosarcoma (OS): risk factors and prognosis. Results of the cooperative OS study group COSS [#1674]. Proc Am Soc Clin Obstet 1996; 15:520.
9. Picci P, Sangiorgi L, Bahamonde L. Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcoma of the extremities. Ann Oncol 1997; 8:899-903.
10. Bacci G, Ferrari S, Longhi A, et al. Local recurrence (L) in non-metastatic osteosarcoma of the extremities (OE) treated with neoadjuvant chemotherapy (NC) the Rizzoli experience [#1786]. Proc Am Soc Clin Oncol 1997; 16:496a.
11. Bacci G, Ferrari S, Mercuri M, et al. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop Scand 1998; 69:230-6.
12. Marina NM, Pratt CB, Rao BN, et al. Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Cancer 1992; 70:2722-7.
13. Meyers PS, Heller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 1993; 11:449-53.
14. Bacci G, Picci P, Briccoli A, et al. Osteosarcoma of the extremity metastatic at presentation: results achieved in 26 patients treated with combined therapy (primary chemotherapy followed by simultaneous resection of the primary and metastatic lesions). Tumori 1992; 78:200-6.
15. Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol 1998; 16:3641-8.
16. Pacquement H, Kalifa C, Fagnou MC, et al. Metastatic osteogenic sarcoma at diagnosis. Study of 73 cases from the French Society of Pediatric Oncology (SIOP) between 1980 and 1990 (Abstr 0-211). Med Pediatr Oncol 1996; 27:264.
17. Bacci G, Mercuri M, Bricolli A, et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer 1997; 79:245-54.
18. Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol 1995; 24:87-92.
19. Russell J, Adam J, Wheldon TE, et al. The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small cell lung cancer and neuroblastoma grown as multicellular spheroids. Cancer Chemother Pharmcol 1989; 23:111-4.
20. Bacha DM, Caparros-Sison B, Allen JA, et al. Phase I study of carboplatin (CBDCA) in children with cancer. Cancer Treat Rep 1986; 70:865-9.
21. Gaynon PS, Ettinger LJ, Moel D, et al. Pediatric phase I trial of carboplatin: a Children’s Cancer Study Group report. Cancer Treat Rep 1987; 71:1039-42.
22. Ettinger LJ, Gaynon PS, Krailo MD, et al. A phase II study of carboplatin in children with recurrent or progressive solid tumors. A report from the Children’s Cancer Group. Cancer 1994; 73:1297-301.
23. Ozols RF, Ostchega Y, Curt G, et al. High-dose carboplatin in refractory ovarian cancer patients. J Clin Oncol 1987; 5:197-201.
24. Adams M,. Kerby IJ, Rocker I, et al. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. Acta Oncol 1989; 28:57-60.
25. Mangioni C, Bolis O, Percorelli S, et al. Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Natl Cancer Inst 1989; 81:1464-71.
26. Jacobs RH, Bitran JC, Deutsch M, et al. Phase II study of carboplatin in previously untreated patients with metastatic small cell lung carcinoma. Cancer Treat Rep 1987; 71:311-2.
27. Gore ME, Calvert AH, Smith LE. High-dose carboplatin in the treatment of lung cancer and mesothelioma: A phase I dose-escalation study. Eur J Cancer Clin Oncol 1987; 23:1391-7.
28. Gatzemeier U, Heckmayr M, Neuhauss R, et al. Phase II studies with carboplatin in non-small cell lung cancer. Semin Oncol 1990; 17:25-31.
29. Motzer RJ, Bosl GJ, Tauer K, et al. Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatin. Cancer Treat Rep 1987; 71:197-8.
30. Akaza H, Haiwara M, Deguchi N, et al. Phase II trial of carboplatin in patients with advanced germ-cell testicular tumors and transitional cell carcinomas of the urinary tract. Cancer Chemother Pharmacol 1989; 23:181-5.
31. Horwich D, Dearnalay DP, Duchesne GM, et al. Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. J Clin Oncol 1989; 7:115-6.
32. Oliver RT, Lore S, Ong J. Alternatives to radiotherapy in the management of seminoma. Br J Urol 1990; 65:61-7.
33. Long HJ, Pfeifle DM, Wieand HS. Phase II evaluation of carboplatin in advanced endometrial carcinoma. J Natl Cancer Inst 1988; 80:276-8.
34. Green III, JB Green S, Alberts DS, et al. Carboplatin therapy in advanced endometrial cancer. Obstet Gynecol 1990; 75:696-700.
35. Al Sarraf M, Metch B, Kish J, et al. Platinum analogs in recurrent and advanced head and neck cancer: A Southwest Oncology Group and Wayne State University study. Cancer Treat Rep 1987; 71:723-6.
36. Meyers FJ, Welborn J, Lewis JP, et al. Infusion carboplatin treatment of relapsed and refractory acute leukemia: Evidence of efficacy with minimal extramedullary toxicity at intermediate doses. J Clin Oncol 1989; 7:173-8.
37. Naito K, Kobayashi M, Ayama A, et al. Phase II study of carboplatin in malignant lymphoma. Gan To Kagaku Ryoho 1988; 15:2145-51.
38. Edmonson JH, McCormack GM, Wieand HS, et al. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in Stage III-IV ovarian carcinoma: Comparison of equally myelosuppressive regimens. J Natl Cancer Inst 1989; 81:1500-4.
39. Anderson H, Wagstaff J, Crowther D, et al. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer. Eur J Cancer Clin Oncol 1988; 24:1471-9.
40. Zamboglou N, Pape H, Schnabel T, et al. Combined radiotherapy with cis-or carboplatin in advanced head and neck tumors. Strahlenther Onkol 1989; 165:647-51.
41. Volling P, Schroder M, Rauschning W, et al. Carboplatin. The better platinum in head and neck cancer? Arch Otolaryngol Head Neck Surg 1989; 115:695-8.
42. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993; 11:598-606.
43. Bokemeyer C, Kohrmann O, Tischler J, et al. A randomized trial of cisplatin, etoposide, and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with " good-risk” metastatic non-seminomatous germ cell tumors. Ann Oncol 1996; 7:1015-21.
44. Horiwch A, Sleijfer DR, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997; 15:1844-52.
45. Allen JC, Walker R, Luks E, et al. Carboplatin and recurrent childhood brain tumors. J Clin Oncol 1987; 5:459-63.
46. Castleberry RP, Cantor AB, Green AA, et al. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1994; 12:1616-20.
47. Meyer WH, Pratt CB, Harper J, et al. Ifosfamide (IFOS) and carboplatin (CARBO) window therapy in previously untreated osteosarcoma (OS) (abstr #1410). Proc Am Soc Clin Oncol 1995; 14:442.
48. Meyer WH, Pratt CB, Rao BN, et al. Curative therapy for osteosarcoma without cisplatin: preliminary results of SJCRH OS-91 (abstr #1842). Proc Am Soc Clin Oncol 1997; 16:512a.
49. Gore ME, Fryatt I, Wiltshaw E, et al. Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer 1989; 60:767-9.
50. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
51. Peto R, Pike M, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observations of each patient I: Analysis and examples. Br J Cancer 1977; 35:1-39.
52. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J Royal Stat Soc 1972; 135:185-98.
53. Bergman PJ, MacEwan EG, Kurzman ID, et al. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). J Vet Intern Med 1996; 10:76-81.
54. Ochs JJ, Freeman AI, Douglass Jr, HO et al. Cis-dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 1978; 62:239-45.
55. Jaffe N, Robertson R, Ayala A, et al. Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J Clin Oncol 1985; 3:1101-4.
56. Teicher BA, Holden SA, Eder JP, et al. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res 1989; 49:5994-8.
57. Egorin MJ, Van Echo DA, Tipplin SJ. Pharmacokinetics and dosage reduction of diamminecyclobutanedicarboxylatoplatinum in patients with impaired renal function. Cancer Res 1984; 44:5432-8.
58. Newell DR, Siddik ZH, Gumbrell LA, et al. Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. Eur J Cancer Clin Oncol 1987; 23:1399-405.
59. Kushner BH, Meyers PA, Gerald WL, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing’s sarcoma, in children and young adults. J Clin Oncol 1995; 13:2796-804.
60. Ward WG, Mikaelian K, Dorey F, et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 1994; 12:1849-58.
61. Picci P, Sangiori L, Bahamonde L, et al. Risk factors for local recurrences after limb-salvage surgery for high-grade osteosarcoma of the extremities. Ann Oncol 1997; 8:899-903.
62. Bacci G, Picci P, Ferrari S, et al. Synchronous multifocal osteosarcoma: results in twelve patients treated with neoadjuvant chemotherapy and simultaneous resection of all involved bones. Ann Oncol 1996; 7:864-6.